The earnings call highlighted significant revenue growth and successful launches in nephrology and IDN segments, contributing to a positive outlook. However, challenges such as increased gross to net discounts and declining cash reserves were noted. Despite these challenges, the positive achievements and strategic advancements suggest a generally positive sentiment.

Company Guidance -

Q3 2025

During the scPharmaceuticals second quarter 2025 earnings call, the company provided several key metrics reflecting its financial and operational progress. The company reported $16 million in net revenue for Q2 2025, marking a significant 99% increase over Q2 2024. Additionally, approximately 20,200 FUROSCIX doses were filled, representing a 117% increase from the same period last year and a 45% rise from Q1 2025. The call highlighted a strong uptake in nephrology following its launch in late April, with nephrologists showing faster adoption rates compared to cardiologists. The company also anticipated a positive impact on market penetration due to a growing number of Medicare Part D patients reaching their out-of-pocket maximums. scPharmaceuticals ended Q2 2025 with $40.8 million in cash and cash equivalents, with expectations for quarterly net cash flows to decrease for the rest of the year as revenues increase. The company is on track to submit a supplemental new drug application for an auto-injector, expected to reduce COGS by approximately 75% and drive further growth.

Significant Revenue Growth

In Q2 2025, scPharmaceuticals generated $16 million in net revenue, marking a 99% increase over Q2 2024.

Increase in FUROSCIX Doses

Approximately 20,200 FUROSCIX doses were filled, representing a 117% increase over Q2 2024 and a 45% increase over Q1 2025.

Nephrology Launch Success

Nephrology showed strong enthusiasm for FUROSCIX with faster uptake by nephrologists compared to initial cardiologists. Nephrology is expected to have a meaningful contribution in Q3.

IDN Distribution Strategy

The IDN business exceeded expectations, with performance continuing to grow and beat internal expectations, marking a 70% growth quarter-over-quarter.

Auto-Injector SNDA Submission

The SNDA for the auto-injector is on track for submission, with an anticipated 75% reduction in COGS and increased penetration rates.

scPharmaceuticals (SCPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SCPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.24 / -	-0.75	―	―	―
Aug 07, 2025	2025 (Q2)	-0.30 / -0.34	-0.44	22.73% (+0.10)	―
May 14, 2025	2025 (Q1)	-0.30 / -0.37	-0.36	-2.78% (-0.01)	―
Mar 19, 2025	2024 (Q4)	-0.38 / -0.35	-0.35	0.00% (0.00)	―
Nov 13, 2024	2024 (Q3)	-0.30 / -0.75	-0.41	-82.93% (-0.34)	―
Aug 14, 2024	2024 (Q2)	-0.42 / -0.44	-0.36	-22.22% (-0.08)	―
May 14, 2024	2024 (Q1)	-0.44 / -0.36	-0.3	-20.00% (-0.06)	―
Mar 13, 2024	2023 (Q4)	-0.42 / -0.35	-0.3	-16.67% (-0.05)	―
Nov 08, 2023	2023 (Q3)	-0.36 / -0.41	-0.37	-10.81% (-0.04)	―
Aug 10, 2023	2023 (Q2)	-0.37 / -0.36	-0.35	-2.86% (-0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SCPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$5.01	$4.63	-7.58%
May 14, 2025	$2.24	$2.88	+28.57%
Mar 19, 2025	$3.04	$3.01	-0.99%
Nov 13, 2024	$3.91	$3.36	-14.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.